Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5481-5488

  Murray, James L ^a   Gillogly, Michael ^a   Kawano, Kouichiro ^a   Efferson, Clay L ^a   Lee, Jeffrey E ^a   Ross, Merrick ^a   Wang, Xinhui ^b   Ferrone, Soldano ^b   Ioannides, Constantin G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; ANTIIDIOTYPIC MONOCLONAL ANTIBODY; ANTIIDIOTYPIC MONOCLONAL ANTIBODY MEL 2; ANTIIDIOTYPIC MONOCLONAL ANTIBODY MF11 30; EPITOPE; GAMMA INTERFERON; HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN; HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN[76-84]; HLA A2 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 10; MELANOMA ANTIGEN; MELANOMA VACCINE; MELLIMUNE; MONOCLONAL ANTIBODY; PEPTIDE; PEPTIDE VH[3-11]; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CELL STRAIN A375SM; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN VARIANT; SEQUENCE HOMOLOGY; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; WILD TYPE;

AMINO ACID SEQUENCE; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; CELL DIVISION; EPITOPE MAPPING; EPITOPES; HUMANS; IMMUNIZATION; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MELANOMA; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 3442902815     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0517     Document Type: Article

References (46)

1. Bajetta E, Del Vecchio M, Bernard-Matty C, et al. Metastatic melanoma: chemotherapy. Sem Oncol 2002;29:427-45.
2. Mitchell MS, Harel W, Kempf RA, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990;8:856-69.
3. Morton DL, Foshag JL, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-82.
4. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18:267-9.
5. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:l75-82.
6. Livingston PO, Ragupathi G. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 1997;45:10-9.
7. Mittelman A, Chen ZJ, Kageshita T, et al. Active specific immunotherapy in patients with melanoma: a clinical trial with murine anti-idiotypic monoclonal antibodies elicited with syngeneic anti high molecular weight-melanoma associated antigen (HMW-MAA) monoclonal antibodies. J Clin Invest 1990;86:2136-44.
8. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992;89:466-70.
9. Saleh MN, Lalisan DY Jr, Pride MW, et al. Immunologic response to the bivalent murine anti-id vaccine Melimmune-1 and Melimmune-2 in patients with high risk melanoma without evidence of systemic disease. J Immunother 1997;21:379-88.
10. Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype mimicking disialoganglioside GD2. J Clin Oncol 2000;18:376-84.
11. Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 1994;54:415-21.
12. Mittelman A, Chen GZJ, Wong GY, Liu C, Hirai S, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1995;1:705-13.
13. Quan WD Jr, Dean GE, Spears L, et al. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. J Clin Oncol 1997;15:2103-10.
14. Pride MW, Shuey S, Grillo-Lopez A, et al. Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE®) that mimic the high molecular weight proteoglycan antigen. Clin Cancer Res 1998;4:2363-70.
15. Harper JR, Reisfeld RA. Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan. J Natl Cancer Inst 1983;71:259-63.
16. Chattopadhyay P, Kaveri SV, Byars N, Starkey J, Ferrone S, Raychaudhuri S. Human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1. Cancer Res 1991;51:6045-51.
17. Kageshita T, Kuriya N, Ono T, et al. Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. Cancer Res 1993;53:2830-3.
18. Iida J, Meijne AM, Spiro RC, Roos E, Furcht LT, McCarthy JB. Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. Cancer Res 1995;55:2177-85.
19. Abrams SI, Schlom J. Rational antigen modification as a strategy to upregulate or downregulate antigen recognition. Curr Opin Immunol 2000;12:85-91.
20. + T cells by melanoma-derived altered peptide ligands: Role of melan-A/MART-1 optimized analogues. Cancer Res 2003;63:1560-7.
21. Dohi Y, Yamada K, Ohno N, et al. Naturally occurring cytotoxic T lymphocyte precursors with specificity for an Ig idiotype. J Immunol 1988;14:3804-9.
22. Waters SJ, Bona CA. Characterization of a T-cell clone recognizing idiotypes as tumor-associated antigens. Cell Immunol 1988;111:87-93.
23. Chattopadhyay P, Starkey J, Raychaudhur S. Analysis of anti-tumor antibodies in mice and rabbits induced by monoclonal anti-idiotope antibodies. J Immunol 1991;14:2055-62.
24. Kusama M, Kageshita T, Chen ZJ, Ferrone S. Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J Immunol 1989;143:3844-52.
25. McMichael AJ, Parham P, Rust N, Brodsky FA. monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum Immunol 1980;1:121-9.
26. Hogan KT, Clayberger C, Bernhard EJ, et al. A panel of unique HLA-A2 mutant molecules define epitopes recognized by HLA-A2-specific antibodies and cytotoxic T lymphocytes. J Immunol 1989;142:2097-104.
27. Iwasaki Y, Takabatake H, Shinji T, Monestier M, Ferrone S. Structural profile of idiotype. anti-idiotype and anti-anti-idiotype monoclonal antibodies in the HLA-DQ3 antigenic system. Eur J Immunol 1994;24:2874-81.
28. Fisk B, Savary C, Hudson JM, et al. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction. J Immunother Emphasis Tumor Immunol 1995;18:197-209.
29. Fisk B, Blevins TL, Wharton JT. Identification of a immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1998;181:2109-17.
30. Murray JL, Gillogly ME, Przepiorka D, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002;11:3407-18.
31. Pluschke G, Vanek M, Evans A, et al. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 1996;93:710-5.
32. Toes RE, Nussbaum AK, Degermann S, et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 2001;194:1-12.
33. Nielsen M, Lundegaard C, Worning P, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003;5:1007-17.
34. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Idiotype vaccination against murine B cell lymphoma humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990;145:1029-36.
35. Wilson A, George AJT, King C, Stevenson FK. Recognition of a B cell lymphoma by anti-idiotypic T cells. J Immunol 1990;145:3937-43.
36. Saha A, Chatterjee SK, Foon KA, Primus FJ, Bhattacharya-Chatterjee M. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Cancer Res 2003;63:2844-55.
37. Fagerberg J, Hjelm AL, Ragnhammar P, Frödin JE, Wigzell H, Mellstedt, H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 1995;55:1824-7.
38. Durrant LG, Buckley TJD, Denton GWL, Hardcastle JD, Sewell HF, Robins RA. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res 1994;54:4837-40.
39. Chatterjee SJ, Tripathi PK, Chakraborty M, et al. Molecular mimicry of carcinembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res 1998;58:1217-24.
40. Reece DE, Foon KA, Chatterjee MB, et al. Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastasis breast cancer. Clin Br Cancer 2003;4:S152-7.
41. Somasundaram R, Zaloudik J, Jacob L, et al. Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol 1995;155:3253-61.
42. Wen Y, Barlogie B, Yi Q. Idiotype-specific cytotosic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 2001;97:1750-5.
43. Rafiq J, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Investig 2002;110:71-9.
44. Messaoudi I, Guevara Patino JA, Dyall R, LeMaoult J, Nikolich-Zugich J. Direct link between mhc polymorphism. T cell avidity, and diversity in immune defense. Science 2002;298:1797-800.
45. Degano M, Garcia KC, Apostolopoulos V, Rudolph MG, Teyton L, Wilson IA. A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. immunity 2001;12:251-61.
46. Natali PG, Bigotti A, Cavaliere R, et al. Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. Cancer Res 1985;45:2883-99.